Should be no reason why there would be any issues with toxicity in Part A
Part B is very interesting, dosing patients with fibrosis...
Ann: AD-214 clinical trial approval, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
-0.001(4.00%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.4¢ | $4.862K | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 422425 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 154221 | 1 |
View Market Depth
| Last trade - 10.35am 16/07/2024 (20 minute delay) ? |
| 1AD (ASX) Chart |